These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 33460613)

  • 21. PDGFs and their receptors.
    Kazlauskas A
    Gene; 2017 May; 614():1-7. PubMed ID: 28267575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim.
    Byerly JH; Port ER; Irie HY
    Breast Cancer Res; 2020 Jun; 22(1):72. PubMed ID: 32600444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells.
    Yamashita N; Kanno Y; Saito N; Terai K; Sanada N; Kizu R; Hiruta N; Park Y; Bujo H; Nemoto K
    Biochem Biophys Res Commun; 2019 Aug; 516(3):693-698. PubMed ID: 31253396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-κB signaling pathways.
    Ahmad A; Wang Z; Kong D; Ali R; Ali S; Banerjee S; Sarkar FH
    Breast Cancer Res Treat; 2011 Feb; 126(1):15-25. PubMed ID: 20379844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
    Xu L; Tong R; Cochran DM; Jain RK
    Cancer Res; 2005 Jul; 65(13):5711-9. PubMed ID: 15994946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Mar; 129():65-83. PubMed ID: 29408302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 28. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
    Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
    Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
    Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quercetin regulates β-catenin signaling and reduces the migration of triple negative breast cancer.
    Srinivasan A; Thangavel C; Liu Y; Shoyele S; Den RB; Selvakumar P; Lakshmikuttyamma A
    Mol Carcinog; 2016 May; 55(5):743-56. PubMed ID: 25968914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment.
    Bodenstine TM; Chandler GS; Reed DW; Margaryan NV; Gilgur A; Atkinson J; Ahmed N; Hyser M; Seftor EA; Strizzi L; Hendrix MJ
    Cell Cycle; 2016 May; 15(9):1295-302. PubMed ID: 27007464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PDGF-D/PDGFRβ promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway.
    Zhang H; Sun JD; Yan LJ; Zhao XP
    Biochem Biophys Res Commun; 2016 Sep; 478(2):845-51. PubMed ID: 27507215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of cell-penetrant kinin B1 receptor antagonists in human triple-negative breast cancer cells.
    Dubuc C; Savard M; Bovenzi V; Lessard A; Côté J; Neugebauer W; Geha S; Chemtob S; Gobeil F
    J Cell Physiol; 2019 Mar; 234(3):2851-2865. PubMed ID: 30132865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An oncogenic activity of PDGF-C and its splice variant in human breast cancer.
    Bottrell A; Meng YH; Najy AJ; Hurst N; Kim S; Kim CJ; Kim ES; Moon A; Kim EJ; Park SY; Kim HC
    Growth Factors; 2019 Aug; 37(3-4):131-145. PubMed ID: 31542979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.